Pakistan's pharmaceutical sector faced significant supply and production concerns in February 2023 as manufacturers warned regulators that shortages of raw materials and rising costs were making continued production difficult.

Companies Warned About Production

Reports at the time said pharmaceutical companies informed the Drug Regulatory Authority of Pakistan that production could be affected by difficulties obtaining raw materials and unresolved pricing concerns.

Raw Materials and Import Constraints

The pharmaceutical industry relies on imported active ingredients and other inputs for many medicines. Industry representatives cited foreign-exchange constraints, currency depreciation and rising production costs.

Government Response

Health officials discussed measures intended to maintain medicine availability while the industry sought action on raw-material imports and pricing.

A Developing Situation

The manufacturers' warnings concerned potential production disruption rather than proof that all medicine production had stopped.

This article describes the situation reported in February 2023 and should be read as a historical news report rather than current information about medicine availability.